Recombinant Human Serine-rich and transmembrane domain-containing protein 1 (SERTM1)

What is SERTM1 and where is it located in the human genome?

SERTM1 (Serine-rich and Transmembrane Domain-containing Protein 1) is a protein-coding gene also known as C13orf36 . It is located on chromosome 13 at position q13.3, with specific genomic coordinates NC_000013.11 (36674020..36697839) . The gene contains 2 exons according to current annotation .

The protein is localized in intracellular membrane-bounded organelles based on recent characterization . This subcellular localization is important for understanding its potential functional roles in cellular processes.

What is the molecular structure of SERTM1?

SERTM1 is characterized by:

• Serine-rich regions: Areas with high serine amino acid content, which are often sites for post-translational modifications

• Transmembrane domain: A hydrophobic region that anchors the protein to cellular membranes

• Signal sequence: Likely contains targeting information for proper cellular localization

While the complete three-dimensional structure has not been fully characterized based on available data, SERTM1 shares structural features with other serine-rich proteins that often function in protein-protein interactions and cellular adhesion .

How does SERTM1 compare to other serine-rich proteins across species?

Serine-rich proteins constitute a diverse functional group across organisms:

In bacterial systems, serine-rich repeat proteins (SRRPs) are well-characterized as cell surface adhesins that contribute to pathogenesis and mediate attachment to surfaces .

How can I clone and express recombinant human SERTM1?

For successful cloning and expression of recombinant SERTM1, follow this methodological workflow:

• Gene synthesis or amplification options:

  • Commercial gene synthesis optimized for your expression system

  • PCR amplification from human cDNA libraries using primers designed from reference sequence

  • Acquire validated ORF clones from repositories (similar to available hedgehog SERTM1 clones)

• Vector selection considerations:

  • For mammalian expression: pcDNA3.1 series vectors are suitable

  • Include appropriate tags (His, FLAG, GFP) for detection and purification

  • Consider inducible expression systems for potentially toxic proteins

• Expression systems:

  • Mammalian cells (HEK293, CHO) for proper post-translational modifications

  • Bacterial systems for high yield if glycosylation is not crucial

  • Cell-free systems for rapid screening

• Expression verification methods:

  • Western blotting with tag-specific or SERTM1-specific antibodies

  • RT-PCR for transcript verification

  • Fluorescence microscopy for tagged constructs

What purification strategies are optimal for recombinant SERTM1?

Purifying transmembrane proteins like SERTM1 requires specialized approaches:

• Membrane extraction:

  • Gentle detergents (DDM, CHAPS, Triton X-100) to solubilize from membranes

  • Buffer optimization to maintain protein stability

  • Consider nanodiscs or liposomes for maintaining native conformation

• Chromatography workflow:

  • Affinity chromatography using expressed tags (Ni-NTA for His-tags)

  • Ion exchange chromatography for further purification

  • Size exclusion chromatography for final polishing and buffer exchange

• Quality control:

  • SDS-PAGE for purity assessment

  • Mass spectrometry for identity confirmation

  • Circular dichroism for secondary structure verification

  • Dynamic light scattering for aggregation assessment

• Storage considerations:

  • Glycerol addition (10-20%) for stability

  • Aliquoting to avoid freeze-thaw cycles

  • Lyophilization may be suitable depending on stability

What approaches are effective for studying SERTM1 expression patterns?

Multiple complementary techniques can characterize SERTM1 expression:

• Transcriptomic approaches:

  • RNA-seq for quantitative expression profiling across tissues

  • Single-cell or single-nucleus RNA-seq for cellular resolution

  • smFISH (single-molecule fluorescent in situ hybridization) for spatial resolution

• Protein detection methods:

  • Immunohistochemistry using validated antibodies

  • Western blotting for quantification across tissues/conditions

  • Proteomics for comprehensive protein identification

• Reporter systems:

  • SERTM1 promoter-driven reporters for expression dynamics

  • CRISPR/Cas9 knock-in fluorescent tags for endogenous expression

• Regulatory analysis:

  • SCENIC (Single-Cell Regulatory Network Inference) for regulatory network analysis

  • ChIP-seq for identifying transcription factors binding to SERTM1 promoter

How can I investigate the function of SERTM1 in cellular processes?

To elucidate SERTM1 function, implement these methodological approaches:

• Loss-of-function studies:

  • CRISPR/Cas9 knockout or knockdown

  • siRNA/shRNA knockdown for temporal control

  • CRISPR interference for targeted repression

• Gain-of-function studies:

  • Overexpression analysis with wild-type SERTM1

  • Domain-specific mutants to identify functional regions

  • Inducible expression systems for temporal control

• Interaction studies:

  • Immunoprecipitation followed by mass spectrometry

  • Yeast two-hybrid or mammalian two-hybrid screening

  • Proximity labeling (BioID, APEX) for interaction networks

  • Split-GFP complementation for direct interactions

• Functional assays:

  • Cell adhesion, migration, or proliferation assays

  • Subcellular trafficking analysis

  • Signal transduction pathway analysis

What are the predicted post-translational modifications of SERTM1 and how can I study them?

Serine-rich proteins typically undergo extensive post-translational modifications:

• Predicted modifications:

  • O-linked glycosylation on serine residues (typical for SRRPs)

  • Phosphorylation on serine/threonine residues

  • Potentially other modifications (acetylation, ubiquitination)

• Experimental detection methods:

  • Mass spectrometry for comprehensive PTM mapping

  • Glycoprotein-specific staining (PAS, lectin blotting)

  • Phospho-specific antibodies if available

  • Enzymatic treatments (phosphatases, glycosidases) followed by mobility shift analysis

• Functional impact assessment:

  • Site-directed mutagenesis of modified residues

  • Comparison of modified vs. unmodified protein properties

  • Interactome analysis in presence/absence of modifications

• Bioinformatic prediction tools:

  • NetOGlyc for O-glycosylation sites

  • NetPhos for phosphorylation sites

  • ModPred for multiple PTM prediction

How does SERTM1 potentially function in gene regulatory networks?

Understanding SERTM1's role in gene regulatory networks requires integrated approaches:

• Network analysis:

  • SCENIC pipeline for single-cell regulatory network inference

  • Connection Specificity Index (CSI) to detect regulatory modules

  • Integration of transcription factor binding data

• Key analytical concepts:

  • Regulon activity scores (RAS) to quantify regulatory influence

  • Target gene enrichment analysis

  • Co-expression network construction

• Experimental validation:

  • ChIP-seq to identify direct binding targets

  • ATAC-seq to assess chromatin accessibility

  • CUT&RUN for high-resolution transcription factor binding

• Data integration:

  • Combined analysis of gene expression, chromatin accessibility, and protein interaction data

  • Transcription factor motif enrichment analysis

  • Pathway analysis of affected genes

How should I analyze SERTM1 sequence variations across populations?

For comprehensive analysis of SERTM1 genetic variation:

• Data acquisition:

  • Query NCBI Variation Viewer for SERTM1 variants

  • Access population databases (gnomAD, 1000 Genomes)

  • Evaluate ClinVar for clinically relevant variants

  • Extract data from dbVar for structural variants

• Analytical workflow:

  • Variant calling from sequencing data

  • Annotation using tools like VEP, ANNOVAR

  • Functional prediction using SIFT, PolyPhen-2, CADD

  • Population frequency assessment

• Specific considerations for SERTM1:

  • Focus on variants affecting:

    • Transmembrane domains (localization impact)

    • Serine-rich regions (modification sites)

    • Conserved functional motifs

  • Correlation with expression data when available

• Visualization approaches:

  • Lollipop plots for variant distribution

  • Heatmaps for population frequency comparisons

  • Protein structure mapping (if available)

What bioinformatic approaches can predict SERTM1 structure-function relationships?

Employ these computational methods for SERTM1 structure-function analysis:

• Sequence-based predictions:

  • TMHMM or TOPCONS for transmembrane domain prediction

  • InterPro and Pfam for domain identification

  • SignalP for signal peptide prediction

  • Conservation analysis across orthologs

• Structural modeling:

  • AlphaFold2 for 3D structure prediction

  • Molecular dynamics simulations for conformational analysis

  • Comparative modeling if suitable templates exist

  • Membrane protein-specific modeling tools

• Functional inference:

  • Gene Ontology term enrichment

  • Protein-protein interaction network analysis

  • Pathway enrichment based on interacting partners

  • Text mining of literature for functional associations

• Integration strategies:

  • Consensus predictions from multiple methods

  • Experimental validation of key predictions

  • Iterative refinement of models with new data

How can I interpret SERTM1 localization data in the context of cellular compartments?

For accurate interpretation of SERTM1 subcellular localization:

• Experimental approaches:

  • Immunofluorescence with organelle markers

  • Subcellular fractionation followed by Western blotting

  • Electron microscopy for high-resolution localization

  • Live-cell imaging with fluorescently tagged constructs

• Quantitative analysis:

  • Colocalization coefficients with known markers

  • Intensity correlation analysis

  • Object-based colocalization measurements

  • Dynamic tracking for trafficking studies

• Contextual interpretation:

  • Based on current data, SERTM1 localizes to intracellular membrane-bounded organelles

  • Consider physiological relevance of localization

  • Evaluate potential transport between compartments

  • Assess changes in localization under different conditions

• Functional implications:

  • Correlate localization with potential interaction partners

  • Consider impact of mutations on localization

  • Evaluate role in organelle-specific processes

What is known about SERTM1 involvement in human diseases?

While specific disease associations for SERTM1 are not detailed in the available search results, researchers could investigate:

• Genetic association approaches:

  • Analysis of variants in ClinVar database

  • GWAS data examination for disease-associated SNPs

  • Copy number variation analysis in disease cohorts

• Expression analysis in disease:

  • Differential expression between healthy and diseased tissues

  • Single-cell analysis to identify cell type-specific alterations

  • Correlation with disease progression markers

• Functional studies:

  • CRISPR/Cas9 editing of disease-associated variants

  • Patient-derived cell models for functional assessment

  • Animal models with SERTM1 alterations

• Potential research directions:

  • Investigation in membrane trafficking disorders

  • Assessment in cellular adhesion pathologies

  • Evaluation in signaling pathway dysregulation

How can I design experiments to investigate SERTM1 as a potential therapeutic target?

Methodological approaches to evaluate SERTM1 as a therapeutic target:

• Target validation:

  • Confirmation of disease-relevant expression

  • Knockdown/knockout phenotype assessment

  • Structure-function relationship characterization

• Compound screening:

  • Development of functional assays for high-throughput screening

  • Fragment-based screening against purified protein

  • Virtual screening using computational models

  • Antibody or peptide-based targeting strategies

• Mechanism investigation:

  • Binding site identification

  • Affinity and specificity determination

  • Effect on downstream pathways

  • Cellular phenotypic responses

• Delivery approaches:

  • Small molecule inhibitors for transmembrane regions

  • Antibody-based therapies for accessible domains

  • RNA-based approaches for expression modulation